Taken together, our findings show that miR‐520b promotes NSCLC tumourigenesis via SPOP‐GLI2/3 axis, thus providing miR‐520b as a potential diagnostic biomarker and therapeutic target for NSCLC. This evidence concerns the gene GLI2 and non-small cell lung carcinoma.